Q-omics provides the consensus-scored SMIM9 profile across patient tissues and cancer cell-line models. SMIM9 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SMIM9 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, SMIM9 RNA expression shows 6,670 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, KIRC, and STAD as cancer lineages where SMIM9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM9 survival associations across molecular data types. SMIM9 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM9 RNA expression–survival associations across cancer types. High SMIM9 expression shows unfavorable associations in LUSC, KIRP, LGG, ACC, UVM and HNSC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify LUSC as the clearest survival context for SMIM9 RNA expression.
This table summarizes SMIM9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM9 shows lower tumor expression in BRCA, LUSC, LUAD and THCA and higher tumor expression in KIRC and UCEC. The KIRC box plot shows higher SMIM9 RNA expression in tumor versus normal tissue (log2 FC = +0.097, t-test p < 0.001).
This table shows molecular features associated with SMIM9 in patient tissues and cancer cell lines. In patient samples, SMIM9 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
